Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. BTG was established in 1981, as British Technology Group, following the merger of the National Research
Development Corporation and the National Enterprise Board. However, the company's origins date back to 1948. The
company was privatised as BTG through an employee and management buy out in 1992 and was listed on the London
Stock Exchange in 1995.
BTG is a global technology commercialisation company, operating from offices in Europe, North America and Japan. Its
central strategy is to create a sustainable, profitable business by acquiring, developing and commercialising life and
physical science technologies. The company's business model is characterised by investment in the early years with
value generation commencing from three to five years or more. BTG creates value in the intervening period by securing
strong intellectual property (IP) protection, developing the technology and determining the optimum route for realising
value.